Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2023
PHARMAC’s new equity policy
6 December 2023 - PHARMAC is drafting its first Equity Policy which outlines the mahi PHARMAC does, can do, or needs ...
Posted by Michael Wonder on 03 Nov 2022
Advocate 'gutted' as PHARMAC reviews blanket funding of child cancer medicines
2 November 2022 - Rule 8.1b of the Pharmaceutical Schedule allows all child cancer medicines to be funded by PHARMAC. ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use ...
Posted by Michael Wonder on 08 Dec 2021
Funding Keytruda for melanoma but not for lung cancer is racist, health advocates say
8 December 2021 - PHARMAC has been accused of institutional racism and breaching the Treaty of Waitangi for funding drugs ...
Posted by Michael Wonder on 07 Feb 2021
Modifying NICE’s approach to equity weighting
7 February 2021 - The UK’s NICE recently launched a consultation on the methods it uses to evaluate new health technologies, ...
Posted by Michael Wonder on 03 Nov 2020
PHARMAC funding resources to focus on medicines access equity
3 November 2020 - PHARMAC is pleased to announce the launch of He Ako Hiringa, a clinical education provider with ...
Posted by Michael Wonder on 21 Oct 2020
Access to the latest and most effective diabetes drugs depends on where you live and what you earn
21 October 2020 - Access to the latest and most effective drugs for Australians with diabetes can depend on where ...
Posted by Michael Wonder on 17 Sep 2020
Rare Disorders New Zealand supports Human Rights Commission case against PHARMAC
17 September 2020 - Rare Disorders New Zealand supports patient advocate Fiona Tolich’s Human Rights Commission case against PHARMAC for ...
Posted by Michael Wonder on 28 Jul 2020
PHARMAC report: should rich people get subsidised medicine?
29 July 2020 - Should wealthy New Zealanders have access to subsidised medicines when they could be investing in better ...
Posted by Michael Wonder on 22 Jun 2020
It’s time to put fairness into focus
19 June 2020 - Medicines New Zealand is today launching a digitally-enabled public awareness platform Fairness in Focus. ...
Posted by Michael Wonder on 10 Apr 2019
ALP cancer plan ‘divisive, inequitable’
11 April 2019 - Labor’s decision to prioritise fee relief for cancer patients is a departure from its previous policies ...
Posted by Michael Wonder on 13 Dec 2018
Frustrated at cancer treatment inequity
13 December 2018 - As appointed ambassador for the Lung Foundation NZ, I feel very frustrated the Government will not ...
Posted by Michael Wonder on 30 Jul 2018
Health system neglects vulnerable Australians: Grattan Institute report
30 July 2018 - Vulnerable Australians are being neglected by a primary health system that is poorly integrated, lacks direction ...
Posted by Michael Wonder on 28 Jul 2018
Tackling inequalities to improve wellbeing in New Zealand
28 July 2018 - In May, 2018, Jacinda Ardern's New Zealand Government announced their first budget and, in a world first, ...